Ovarian Neoplasms
📧 Sign up to get email alerts when something new happens for Ovarian Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Rubraca (rucaparib camsylate) — pharmaand GmbH
The EMA authorises Rubraca (rucaparib camsylate) for ovarian neoplasms, with pharmaand GmbH as the marketing authorisation holder.
-
EMA approval · 2026-08-12EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple indications across ovarian, breast, pancreatic, and castration-resistant pro…
-
EMA approval · 2026-07-20EMA Authorised: Yondelis (trabectedin) — Pharma Mar S.A.
Authorised status for Yondelis (trabectedin) in the EU for ovarian neoplasms and sarcoma.
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-06-10EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited
The EMA authorised Zejula (niraparib tosilate monohydrate) for ovarian, fallopian tube, and peritoneal neoplasms, under GlaxoSmithKline Trad…
-
EMA approval · 2026-06-03EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple neoplasms including ovarian, breast, pancreatic, and castration-resistant pr…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells [Phase 1]
Phase 1 clinical trial evaluating autologous CAR-T cells targeting B7-H3 (iC9-CAR.B7-H3 T Cells) for ovarian cancer, currently recruiting at…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy [NA]
Clinical trial update for the OV Precision study evaluating tumor- and patient-specific cancer therapy in ovarian and fallopian tube neoplas…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: The Value of the O-RADS Radiological Classification in Predicting the Malignancy of Ovarian Masses in Children
This clinical trial update assesses whether the O-RADS radiological classification can predict malignancy in pediatric ovarian masses. The s…
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: Spectroscopy in Ovarian Cancer
The University of Exeter conducted a completed clinical trial evaluating spectroscopy techniques in ovarian cancer.
-
EMA approval · 2025-11-27EMA Authorised: Rubraca (rucaparib camsylate) — pharmaand GmbH
The EMA has authorised Rubraca (rucaparib camsylate) in the EU for ovarian neoplasms. The marketing authorisation holder is pharmaand GmbH.
-
EMA approval · 2025-11-26EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited
The EMA authorised Zejula for fallopian tube neoplasms, peritoneal neoplasms, and ovarian neoplasms. GlaxoSmithKline Trading Services Limite…
-
CLINICAL_TRIALS research · 2025-10-29Clinical Trial Update: A Trial of Vigil for Participants With Ovarian Cancer [Phase 2]
Phase 2 trial update for Gradalis' Vigil in ovarian cancer, noting the study is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Additive Role of ADC Value to ORADS in Adnexal Lesions
A completed clinical trial evaluated whether adding apparent diffusion coefficient (ADC) values to the ORADS system improves characterizatio…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) [Phase 2]
Merck completed a Phase 2 trial (MK-7684A-005) evaluating MK-7684A with or without other anticancer therapies in selected solid tumors.
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions
A study evaluating ultrasound-guided transvaginal aspiration of cystic pelvic lesions is currently recruiting. Sponsored by Universitaire Zi…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection
A completed trial evaluating IOTA ultrasound criteria combined with serum CA-125 for detecting ovarian malignancy. The study is sponsored by…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Diagnosing Ovarian Cysts - the DOC Study
Completed clinical trial from Rigshospitalet, Denmark, the DOC Study, evaluating diagnostic methods for ovarian cysts and their ability to d…
-
EMA approval · 2025-04-03EMA Authorised: Yondelis (trabectedin) — Pharma Mar S.A.
EU marketing authorisation granted for Yondelis (trabectedin) for ovarian neoplasms and soft tissue sarcoma.
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass
This clinical trial update indicates that Cleo Diagnostics Ltd is recruiting participants for a study evaluating a diagnostic test to assess…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Cancer Loyalty Card Study
Completed status for the Cancer Loyalty Card Study (NCT03994653) sponsored by Imperial College London, with results posted for ovarian neopl…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea
A post-marketing surveillance study of niraparib in adults with approved indications in South Korea has completed.
-
CLINICAL_TRIALS research · 2024-11-25Clinical Trial Update: Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors [NA]
A trial update reports the establishment and clinical application of an AI-based multimodal diagnostic system for ovarian tumors, with the s…